GenIP^® provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services. GenIP is quoted on the AIM market of the London Stock Exchange (AIM: GNIP) and is headquartered in the UK.

With the pace of innovation quickening, research institutions of all types have a recurring need to assess and commercialise their most promising innovations. Minimizing adverse selection is critical to help bring the best technologies to market and produce meaningful returns on limited amounts of invested capital.

Commercialised university-developed discoveries that can enhance people’s lives

We believe that when you couple commercialisation ready, compelling University IP with experienced management, vibrant companies will emerge, returns on invested capital will outperform the sector and exits will occur faster. When we realise exits, the group’s goal is to distribute a portion of the proceeds as a special dividend to our shareholders.